BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Study summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Eligibility
Sex
ALL
Min age
6 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Must have completed Study 111-301
* Female \>= 10 years old or who have begun menses must have a negative pregnancy test at the Baseline Visit and be willing to have additional pregnancy tests during the study
* If sexually active, willing to use a highly effective method of contraception while participating in the study
* Are willing and able to perform all study procedures
* Parent(s) or guardian(s) are willing and able to provide written, signed informed consent after the nature of the study has been explained and prior to performance of any research-related procedure. Also, subjects under the age of majority are willing and able to provide written assent (if required by local regulations or the IRB/IEC) after the nature of the study has been explained and prior to performance of any research-related procedure. Subjects who reach the age of majority in their country while the study is ongoing will be asked to provide their own written consent again upon reaching the legal age of majority.
Exclusion Criteria:
* Permanently discontinued BMN 111 or placebo prior to completion of the 111-301 study
* Have a clinically significant finding or arrhythmia on Baseline ECG that indicates abnormal cardiac function
* Evidence of decreased growth velocity (\<1.5 cm/year) as assessed over a period of at least 6 months or of growth plate closure (proximal tibia, distal femur) through bilateral lower extremity X-rays.
* Require any investigational agent prior to completion of study period
* Current therapy with medications known to alter renal function
* Pregnant or breastfeeding or plan to become pregnant during study
* Concurrent disease or condition that, in the view of the investigator, would interfere with study participation or safety evaluations, for any reason.
* Have a condition or circumstance that, in the view of the investigator, places the subject at high risk for poor treatment compliance or for not completing the study.
Primary outcome measure(s)
Change from baselines in mean annualized growth velocity — Through study completion, an average of 1 year Long term efficacy as measured by change in annualized growth velocity
Trial sites (24)
Facility
City
Region
Status
Children's Hospital & Research Center Oakland
Oakland
California
Harbor - UCLA Medical Center
Torrance
California
Alfred I. duPont Hospital for Children
Wilmington
Delaware
Emory University
Atlanta
Georgia
Ann and Robert H. Lurie Children's Hospital of Chicago
Institut Catala de Traumatologica I Medicina de l'Esport
Barcelona
Spain
Hospital Sant Joan de Deu
Barcelona
Spain
Hospital Universitario Virgen de la Victoria
Málaga
Spain
Acibadem University School of Medicine
Istanbul
Turkey (Türkiye)
Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital
London
United Kingdom
Sheffield Children's NHS Foundation Trust
Sheffield
United Kingdom
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.